Fasenra (Benralizumab) for COPD

Overview
Fasenra is a prescription medication approved by the Food and Drug Administration (FDA) to treat severe asthma in people age 12 and older. Fasenra may be prescribed in cases of asthma that test positive for an eosinophilic phenotype. Fasenra is also known by its drug name, Benralizumab.

Fasenra is an immunomodulator, or in other words, a drug that modulates the immune system. It is considered a biologic. Fasenra is a genetically engineered antibody, or protein used by the immune system to identify and neutralize substances. Fasenra is designed to interfere with interleukin-5 receptor alpha, a chemical messenger involved in autoimmune attacks.

In some people with asthma, elevated levels of one type of white blood cell called eosinophils contributed to airway inflammation and airway hyper-responsiveness. Fasenra is believed to work by reducing the number of eosinophils.

How do I take it?
Fasenra is administered by subcutaneous injection.

Fasenra is taken once every four weeks for three doses, and once every eight weeks after that.

Side effects
The FDA-approved label for Fasenra lists common side effects including headache and sore throat.

Rare but serious side effects listed for Fasenra include severe allergic reactions.

For more details about this treatment, visit:

Fasenra– AstraZeneca
https://www.fasenra.com/